StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Eslicarbazepine Acetate

HCID 179344
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
236395-14-5
Standard-SMILES
CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21
InChIKey
QIALRBLEEWJACW-INIZCTEOSA-N
Summenformel
C17H16N2O3
Durchschnittliche Molmasse
296,32 g/mol
Monoisotopische Masse
296,11609238

Überblick

Eslicarbazepine acetate is the acetate ester, with S configuration, of licarbazepine. An anticonvulsant, it is approved for use in Europe and the United States as an adjunctive therapy for epilepsy. It has a role as an anticonvulsant and a drug allergen. It is a carboxamide, an acetate ester, a dibenzoazepine and a member of ureas. It is functionally related to a licarbazepine.

Namen und Bezeichner

Bevorzugter Name
Eslicarbazepine Acetate
IUPAC
[(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate
Englischer Name
Bia 2-093
Summenformel
C17H16N2O3
Molmasse
296.32

Namen und Synonyme

Eslicarbazepine acetate236395-14-5BIA 2-093ZebinixAptiomExaliefStedesaErelibPazzulBIA-2-093SEP-0002093BEA68ZVB2K
Weitere Namen anzeigen
Sep 0002093BIA 2-093[B5435]Eslikazepine AcetateS-Licarbazepine AcetateEslicarbazepineAcetate>
CHEBI:87016BIA-2093SEP00020935H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-DTXSID90178308(10S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate(10S)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE, 10-(ACETYLOXY)-10,11-DIHYDRO-, (10S)-

Datenbank-Bezeichner

CAS
236395-14-5
PubChem CID
179344
DTXSID
DTXSID90178308
ChEMBL
CHEMBL87992
ChEBI
CHEBI:87016
UNII
BEA68ZVB2K
EC Number
636-617-2
Nikkaji
J1.143.147J

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2
Polarare Oberfläche (TPSA)
72,6 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
2
Schwere Atome
22
Formalladung
0
Komplexität
440

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
SolubilityWater solubility of eslicarbazepine acetate is low at less than 1 mg/mL including at different pH values. Its main metabolite eslicarbazepine has a greater water solubility of 4.2 mg/mL.
Human Drugs · 3 Einträge

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
183 · 183-185°C
Siedepunkt
427.4 · 427.4±55.0 °C(Predicted)
Dichte
1.32 · 1.32
storage temp.
2 · Sealed in dry,2-8°C
Löslichkeit
2 O: · H2O: insoluble
Aggregatzustand
solid
pka
13.97 · 13.97±0.40(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H315 (98.9%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 93 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesSkin Irrit. 2 (98.9%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Eslicarbazepine acetate

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Sicherheitsdaten

wgk
3
hs_code
2934.99.3000
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2STOT SE 3

Chemie und Industrie

Pharmakologische Informationen

Protein Binding · 1 Eintrag

Eslicarbazepine is bound to plasma proteins at a relatively low rate of <40%, independent of concentration. In vitro studies have shown that plasma protein binding is not relevantly affected by the presence of other medications such as warfarin, diazepam, digoxin, phenytoin or tolbutamide. Similarly, the binding of these medications was not significantly affected by the presence of eslicarbazepine.

PharmacodynamicsEslicarbazepine acetate is associated with a dose- and concentration-dependant increase in heart rate and prolongation of PR interval.
Mechanism of Action · 1 Eintrag

Eslicarbazepine acetate is converted to the active metabolite eslicarbazepine which carries out its anticonvulsant activity. The exact mechanism of action is unknown, but it is thought to involve the inhibition of voltage-gated sodium channels. In in vitro electrophysiological studies, eslicarbazepine was shown to inhibit repeated neuronal firing by stabilizing the inactivated state of voltage-gated sodium channels and preventing their return to the activated state. In vitro studies also showed eslicarbazepine inhibiting T-type calcium channels, which likely also has a role in anticonvulsant activity.

Biological Half-LifeThe apparent plasma half-life of eslicarbazepine is 10-20 hours in healthy subjects and 13-20 hours in epilepsy patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.
Metabolism/Metabolites · 1 Eintrag

Eslicarbazepine acetate is rapidly and extensively metabolized to its major active metabolite, eslicarbazepine, via hydrolytic first-pass metabolism. Eslicarbazepine corresponds to about 92% of systemic exposure. Minor active metabolites (R)-licarbazepine and oxcarbazepine consist of <5% of systemic exposure. Active metabolites are then metabolized to inactive glucuronides that correspond to about 3% of systemic exposure. Eslicarbazepine had a moderate inhibitory effect on CYP2C19 and a mild activation of UGT1A1-mediated glucuronidation when studied in human hepatic microsomes. It has been shown to induce CYP3A4 enzymes in vivo.

Zugehörige Reaktionen

6
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 526674
HRID 526674als Edukt
Reaktionsgleichung von HRID 526675
HRID 526675als Edukt
Reaktionsgleichung von HRID 526678
HRID 526678als Produkt
Reaktionsgleichung von HRID 526679
HRID 526679als Produkt
Reaktionsgleichung von HRID 526682
HRID 526682als Produkt
Reaktionsgleichung von HRID 872939
HRID 872939als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Farbe
white
InChI
1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
InChIKey
QIALRBLEEWJACW-INIZCTEOSA-N
SMILES
CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c3ccccc13
FDA Pharmacological Classification · 2 Einträge

ESLICARBAZEPINE ACETATE

Decreased Central Nervous System Disorganized Electrical Activity [PE]; Cytochrome P450 2C19 Inhibitors [MoA]; Cytochrome P450 3A4 Inducers [MoA]

MeSH Pharmacological Classification · 2 Einträge

Drugs used to prevent SEIZURES or reduce their severity.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Absorption, Distribution and Excretion · 4 Einträge

Eslicarbazepine active metabolite has a high bioavailability and reaches peak serum concentration 1-4 hours after a given dose. Eslicarbazepine acetate absorption is not affected by food.

Eslicarbazepine acetate and its metabolites are eliminated primarily via renal excretion. Eslicarbazepine active metabolite is excreted two-thirds in the unchanged form and one-third as a glucuronide conjugate. This accounts for around 90% of total metabolites excreted, with the remaining 10% being minor metabolites. Renal tubular reabsorption is expected to occur with eslicarbazepine.

The apparent volume of distribution of eslicarbazepine is 61.3 L for a body weight of 70 kg based on population PK analysis.

Renal clearance of eslicarbazepine was found to be approximately 20 mL/min in healthy subjects with normal renal function.

Anwendungen · 1 Eintrag

BeschreibungAlthough epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Even when traditional AEDs, such as phenobarbital, phenytoin, carbamazepine, and valproate, control seizure activity, their effectiveness is hampered by considerable side effects and the tendency for drug-drug interactions. Designed for improved efficacy and safety, eslicarbazepine acetate is a third-generation AED that has been approved as adjunctive therapy for partial-onset seizures with or without secondary generalization. As a member of the carbamazepine family (first generation), it is the prodrug of eslicarbazepine and the active metabolite of oxcarbazepine (second generation). .

Ergänzende Hinweise

DefinitionChEBI: The acetate ester, with S configuration, of licarbazepine. An anticonvulsant, it is approved for use in Europe and the United States as an adjunctive therapy for epilepsy.